These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 22796607)
1. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human neuroblastoma through a CD46 and nectin 4-independent pathway. Zhang SC; Cai WS; Zhang Y; Jiang KL; Zhang KR; Wang WL Cancer Lett; 2012 Dec; 325(2):227-37. PubMed ID: 22796607 [TBL] [Abstract][Full Text] [Related]
2. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma. Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685 [TBL] [Abstract][Full Text] [Related]
3. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271 [TBL] [Abstract][Full Text] [Related]
4. Measles vaccine strains for virotherapy of non-small-cell lung carcinoma. Patel MR; Jacobson BA; Belgum H; Raza A; Sadiq A; Drees J; Wang H; Jay-Dixon J; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA J Thorac Oncol; 2014 Aug; 9(8):1101-10. PubMed ID: 25157763 [TBL] [Abstract][Full Text] [Related]
5. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484 [TBL] [Abstract][Full Text] [Related]
6. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267 [TBL] [Abstract][Full Text] [Related]
7. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133 [TBL] [Abstract][Full Text] [Related]
8. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196 [TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422 [TBL] [Abstract][Full Text] [Related]
10. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872 [TBL] [Abstract][Full Text] [Related]
11. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum. Muñoz-Alía MÁ; Nace RA; Tischer A; Zhang L; Bah ES; Auton M; Russell SJ PLoS Pathog; 2021 Feb; 17(2):e1009283. PubMed ID: 33534834 [TBL] [Abstract][Full Text] [Related]
12. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Allen C; Paraskevakou G; Iankov I; Giannini C; Schroeder M; Sarkaria J; Schroeder M; Puri RK; Russell SJ; Galanis E Mol Ther; 2008 Sep; 16(9):1556-64. PubMed ID: 18665158 [TBL] [Abstract][Full Text] [Related]
14. A recombinant measles virus vaccine strain rMV-Hu191 has oncolytic effect against human gastric cancer by inducing apoptotic cell death requiring integrity of lipid raft microdomains. Lv Y; Zhou D; Hao XQ; Zhu MY; Zhang CD; Zhou DM; Wang JH; Liu RX; Wang YL; Gu WZ; Shen HQ; Chen X; Zhao ZY Cancer Lett; 2019 Sep; 460():108-118. PubMed ID: 31226409 [TBL] [Abstract][Full Text] [Related]
15. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. Geoerger B; van Beusechem VW; Opolon P; Morizet J; Laudani L; Lecluse Y; Barrois M; Idema S; Grill J; Gerritsen WR; Vassal G J Gene Med; 2005 May; 7(5):584-94. PubMed ID: 15651070 [TBL] [Abstract][Full Text] [Related]
16. Moesin, and not the murine functional homologue (Crry/p65) of human membrane cofactor protein (CD46), is involved in the entry of measles virus (strain Edmonston) into susceptible murine cell lines. Dunster LM; Schneider-Schaulies J; Dehoff MH; Holers VM; Schwartz-Albiez R; ter Meulen V J Gen Virol; 1995 Aug; 76 ( Pt 8)():2085-9. PubMed ID: 7636492 [TBL] [Abstract][Full Text] [Related]
17. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Anderson BD; Nakamura T; Russell SJ; Peng KW Cancer Res; 2004 Jul; 64(14):4919-26. PubMed ID: 15256464 [TBL] [Abstract][Full Text] [Related]
18. Measles virus infects mouse fibroblast cell lines, but its multiplication is severely restricted in the absence of CD46. Yanagi Y; Hu HL; Seya T; Yoshikura H Arch Virol; 1994; 138(1-2):39-53. PubMed ID: 7980010 [TBL] [Abstract][Full Text] [Related]